Alumis Inc. (ALMS) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Alumis Inc. ALMS 6.12 −3.01%
- Rigel Pharmaceuticals, Inc. RIGL 45.97 −2.71%
Alumis Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Alumis Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($882.6M and $842.4M). Alumis Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs −5,933.5%) and the higher return on invested capital (16.5% vs 0.00%). Across the 15 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Alumis Inc. on 3.
Valuation
Profitability
| Metric | ALMS | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.39% | 65.16% |
| Operating margin | (6,204.39%) | 31.45% | 0.00% |
| Net margin | (5,933.45%) | 116.30% | 0.00% |
| Free cash flow margin | (4,755.33%) | 3.19% | 0.00% |
| Return on equity | (93.65%) | 126.90% | (56.36%) |
| Return on assets | (74.94%) | 88.46% | (48.04%) |
| Return on invested capital | 0.00% | 16.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack